Mar 30, 2012 - 4:24 pm
3/20/2012 - A recent study in the Achieves of Internal Medicine found that during the past decade, some men with low-grade prostate cancer may have been treated with therapies that are too aggressive. The study conducted by Yale School of Medicine researchers, including lead researcher Cary Gross, MD, found that men who are least likely to benefit from treatment—those with short life expectancies and non-aggressive cancers—are more likely to be treated for their cancers than they were a decade ago.
With more than 27 known genotypes, or varieties of prostate cancer, it is vital that each man understands what his diagnostic scores mean and makes informed treatment decisions with his medical team, based upon age, general health and family history. Assessing whether one’s disease appears indolent (non-life threatening) or aggressive is an important step in the process. For many men, the best decision is not to treat immediately but participate in active surveillance. To better inform treatment decisions, PCF has invested more than $5 million in funding for better diagnostics and biomarkers to more accurately pinpoint aggressive versus non-life-threatening cancers so overtreatment can be reduced and more men can be cured.
Several excellent nomograms exists that can help men—of all ages—in the treatment decision process. These are available at:
• Cleveland Clinic: Risk Calculators
• James Buchanan Brady Urological Institute at Johns Hopkins Medicine: The Partin Tables & The Han Tables
• Memorial Sloan-Kettering Cancer Center: Prostate Cancer Nomograms